参与的国内国际临床试验
LancetOncolCisplatinplusgemcitabineversuspaclitaxelplusgemcitabineasfirst-linetherapyformetastatictriple-negativebreastcancer(CBCSG):arandomised,open-label,multicentre,phase3trialXiaojiaWang()
OncotargetFulvestrantmgvs50mginpostmenopausalwomenwithestrogenreceptor-positiveadvancedbreastcancer:arandomized,double-blindregistrationaltrialinChinaXiaojiaWang()
OncotargetOut